Screener
TG Therapeutics TGTX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
FAQ
- What is TG Therapeutics's accounts receivable?
- TG Therapeutics (TGTX) reported accounts receivable of $401.57M in Q2 2026.
- How has TG Therapeutics's accounts receivable changed year-over-year?
- TG Therapeutics's accounts receivable increased by 73.5% year-over-year, from $231.52M to $401.57M.
- What is the long-term trend for TG Therapeutics's accounts receivable?
- Over 4 years (2021 to 2025), TG Therapeutics's accounts receivable has grown at a 285.9% compound annual growth rate (CAGR), from $4.48M to $992.65M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about TG Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude